The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer
Author Information
Author(s): Parsons M F C, Foster P A, Chander S K, Jhalli R, Newman S P, Leese M P, Potter B V L, Purohit A, Reed M J
Primary Institution: Imperial College London
Hypothesis
Is STX243 more active in vivo than the clinically relevant drug 2-methoxyoestradiol and the structurally similar compound STX140?
Conclusion
STX243 is a potent in vivo drug and could be clinically effective at treating a number of oncological conditions.
Supporting Evidence
- STX243 inhibited the growth of MDA-MB-231 xenograft tumors by 72%.
- STX243 was effective against paclitaxel-resistant MCF-7 tumors.
- STX243 showed significant antiangiogenic activity in a Matrigel plug model.
Takeaway
STX243 is a new medicine that helps stop cancer from growing by blocking blood vessel formation, and it works better than some older treatments.
Methodology
The study used four in vivo models to assess the efficacy of STX243 in inhibiting tumor growth and angiogenesis.
Participant Demographics
Adult female rats were used in the pharmacokinetic studies.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website